Boston Scientific Announces Acquisition of Cosman Medical

Go back to Boston Scientific Announces Acquisition of Cosman Medical

Wedbush Raises Price Target on Boston Scientific (BSX) to $25 Following 2Q

July 29, 2016 8:14 AM EDT

Wedbush reiterated a Neutral rating on Boston Scientific (NYSE: BSX), and raised the price target to $25.00 (from $23.00), following the company's 2Q earnings report. Total sales were $2.126 billion, and $80 million ahead of consensus, while adjusted EPS of $0.27 was in line.

Analyst Tao Levy... More